Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

被引：0
作者：
Tessa M. Bosch
Irma Meijerman
Jos H. Beijnen
Jan H. M. Schellens
机构：
[1] The Netherlands Cancer Institute/Slotervaart Hospital,Department of Pharmacy & Pharmacology
[2] University of Utrecht,Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences
[3] Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute,Department of Medical Oncology
来源：
Clinical Pharmacokinetics | 2006年 / 45卷
关键词：
Irinotecan; Acute Myeloid Leukaemia; Acute Lymphoblastic Leukaemia; Breast Cancer Resistance Protein; TPMT Activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is wide variability in the response of individuals to standard doses of drug therapy. This is an important problem in clinical practice, where it can lead to therapeutic failures or adverse drug reactions. Polymorphisms in genes coding for metabolising enzymes and drug transporters can affect drug efficacy and toxicity. Pharmacogenetics aims to identify individuals predisposed to a high risk of toxicity and low response from standard doses of anti-cancer drugs. This review focuses on the clinical significance of polymorphisms in drug-metabolising enzymes (cytochrome P450 [CYP] 2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, dihydropyrimidine dehydrogenase, uridine diphosphate glucuronosyltransferase [UGT] 1A1, glutathione S-transferase, sulfotransferase [SULT] 1A1, N-acetyltransferase [NAT], thiopurine methyltransferase [TPMT]) and drug transporters (P-glycoprotein [multidrug resistance 1], multidrug resistance protein 2 [MRP2], breast cancer resistance protein [BCRP]) in influencing efficacy and toxicity of chemotherapy.
引用
收藏
页码：253 / 285
页数：32
相关论文
共 641 条
[1]  
Dorne J.L.(2004)Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation Fundam Clin Pharmacol 18 609-20
[2]  
Nebert D.W.(2000)Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology Pharmacogenetics 10 279-90
[3]  
Erichsen H.C.(2004)SNPs in cancer research and treatment Br J Cancer 90 747-51
[4]  
Chanock S.J.(2000)Pharmacokinetically guided administration of chemotherapeutic agents Clin Pharmacokinet 39 345-67
[5]  
van den Bongard H.J.(2005)Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review Clin Pharmacokinet 44 147-73
[6]  
Mathot R.A.(2001)Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 597-607
[7]  
Beijnen J.H.(2001)Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism Biol Pharm Bull 24 1427-30
[8]  
de Jonge M.E.(2002)CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 1579-89
[9]  
Huitema A.D.(2002)CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity Clin Pharmacol Ther 71 196-204
[10]  
Schellens J.H.(2003)Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups Pharmacogenetics 13 461-72
12345678910